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ABSTRACT 
Oncogenic rat sarcoma (Ras) is linked to the most fatal cancers such as those of the pancreas, 
colon, and lung. Decades of research to discover an efficacious drug that can block oncogenic 
Ras signaling have yielded disappointing results; thus, Ras was considered “undruggable” 
until recently. Inhibitors that directly target Ras by binding to previously undiscovered 
pockets have been recently identified. Some of these molecules are either isolated from 
natural products or derived from natural compounds. In this review, we described the 
potential of these compounds and other inhibitors of Ras signaling in drugging Ras. We 
highlighted the modes of action of these compounds in suppressing signaling pathways 
activated by oncogenic Ras, such as mitogen-activated protein kinase (MAPK) signaling and 
the phosphoinositide-3-kinase (PI3K) pathways. The anti-Ras strategy of these compounds 
can be categorized into four main types: inhibition of Ras–effector interaction, interference of 
Ras membrane association, prevention of Ras–guanosine triphosphate (GTP) formation, and 
downregulation of Ras proteins. Another promising strategy that must be validated 
experimentally is enhancement of the intrinsic Ras–guanosine triphosphatase (GTPase) 
activity by small chemical entities. Among the inhibitors of Ras signaling that were reported 
thus far, salirasib and TLN-4601 have been tested for their clinical efficacy. Although both 
compounds passed phase I trials, they failed in their respective phase II trials. Therefore, new 
compounds of natural origin with relevant clinical activity against Ras-driven malignancies 
are urgently needed. Apart from salirasib and TLN-4601, some other compounds with a 
proven inhibitory effect on Ras signaling include derivatives of salirasib, sulindac, 
polyamine, andrographolide, lipstatin, levoglucosenone, rasfonin, and quercetin. 
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